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Purpose/Objective: Stereotactic radiotherapy (SRT) of brain 
metastasis can lead to lesion growth after varying time intervals. The 
pathophysiology of this radiation effect, that has to be distinguished 
from regrowth of the tumor, is not well understood. We made cine-
loops of serial MRI scans of patients with this effect in order to 
describe the evolution of SRT associated changes. 
Materials and Methods: Ten patients who had received SRT of brain 
metastases were selected from our departmental database. They had 
been treated on a Novalis (Brainlab, Feldkirchen, Germany). Patients 
received either single doses of 21Gy or 18Gy or three doses of 8Gy. 
Selection criteria for this study were: lesion growth after SRT not 
caused by tumor progression and the availability of at least five three-
monthly follow-up MRI scans. For the cine-loops we used post-
gadolinium 3D T1 weighted images. These MRI scans were co-
registered using iPlan 4.5 (Brainlab). From the pre-SRT MRI the axial 
slice with the largest lesion diameter was selected. For the cine-loop 
we copied the corresponding follow-up MRI images into Microsoft 
Windows Movie Maker (Microsoft Corp. Redmond USA), put them in 
chronological order and used the fading mode for the transitions 
between the separate slices. The ten MRI cine loops were interpreted 
in a joint meeting of the authors. 
Results: In all patients the cine-loops were found to be superior to the 
separate MRI’s for describing and interpreting the events after SRT. 
The sequence of events showed a similar pattern in all patients, but 
the timing of the observed events varied. In the movies we saw partial 
or complete regression of the metastasis first, followed by an 
enlarging area of contrast enhancement in the surrounding brain 
tissue. In five patients the volume of this enhancement eventually 
decreased. Histological examination of the enhancing tissue was 
possible in two patients and confirmed the existence of radiation 
necrosis without residual tumor. 
Conclusions: Cine-loop MRI analysis enabled better understanding of 
the changes that develop in follow-up MRI scans after SRT of brain 
metastases. The cine-loops showed a typical growth pattern after SRT 
with a gradually expanding area of contrast enhancement in the brain 
tissue surrounding the shrinking metastasis. 
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Purpose/Objective: To analyze the toxicity of hypofractionated lung 
SBRT according to QUANTEC recommendations.  
Materials and Methods: From 2002 to 2010, 44 (25 male, 19 female) 
patients with small primary lung cancer or oligometastasis were 
treated with several hypo-fractionation schemes of SBRT at our 
institution. All patients were immobilized using a stereotactic body 
frame, simulated with CT scan and treated with multiple static 6 MV 
beams. A total of 48 lesions were treated, among which 2 patients had 
2 lesions and 1 patient had 3 lesions. The median follow-up was 12 
months. We exported the composite dose volume histograms (DVHs) of 
gross target volume (GTV), planning target volume (PTV) and normal 
lung tissue (whole lung-GTV). For each patient, normal tissue 
complication probability (NTCP) based on the Poisson model was 
calculated using the normal lung DVH, and normalized total dose 
(NTD) volume histograms were generated at 2Gy fractions with a/b = 
3.7 Gy to account for different fractionations. Mean dose and V20 
(%volume receiving 20Gy) of GTV, PTV and normal lung derived from 
DVH/NTDVH were correlated with clinical follow-up. Variable 
importance for projection (VIP) and correlation coefficient (R) were 
calculated for each variable using partial least squares regression 
(PLSR) and logistic regression (LR) to identify the prediction factors 
for normal tissue complications. 
Results: There were 2 (4.2%) local failures, 4 (9.1%) grade 2 
pneumonitis and 3 (6.8%) radiation-induced fibrosis. The <10% 
pneumonitis rate is in line with the QUANTEC report for lung SBRT. 
5/14 (35.7%) of the lesions in right lower lobe developed 
complications, in comparison to 1/16 (6.3%) in right upper and middle 
lobes, 0/5 (0%) in left lower lobe and 1/11 (9.1%) in left upper lobe. 
The most influential VIP for predicting the complications were mean 
GTV dose (VIP =1.500, R=0.145) and GTV volume (VIP=1.451, R=-
0.140), followed by NTCP (VIP=1.106,R=0.107) although the calculated 
probability was much higher than the frequency of complications. LR 
was able to produce a reasonable NTCP curve for these three 
variables. The prediction factors used for conventional lung RT 
complications, i.e., V20, VNTD20, mean dose and mean NTD of normal 
lung had only moderate or low VIP (<0.894), were negatively 
correlated (R between -0.044 and -0.086) and could not be fit to a 
NTCP logistic curve.
Conclusions: Radiation induced complication for SBRT increases with 
the mean GTV dose and cannot be predicted with the known 
prediction factors for conventional lung RT. The cause for higher 
probability of complications for right lower lobe is unclear and needs 
further investigations. NTCP based on Poisson model might be applied 
to lung SBRT but requires different modeling parameters than that 
used for conventional lung RT. 
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Purpose/Objective: To evaluate the feasibility and efficacy of 
Stereotactic body radiation therapy (SBRT) for primary liver lesions 
and liver metastases treated with linear accelerators. 
Materials and Methods: Patients with either hepatocellular 
carcinoma, cholangiocarcinoma or metastatic liver lesions who had 
one to three lesions treated with SBRT in a single institution were 
retrospectively reviewed. Tumor response was evaluated according to 
EASL criteria 3 months after SBRT completion using MRI and/or 
abdominal CT scan. Responses were categorised as: Stable Disease 
(SD), Partial Response (PR),Complete Response (CR), Local Progression 
or Distant Progression in cases of new intra-hepatic lesions out-of-
field or extra-hepatic metastases. Local Control (LC), Progression Free 
Survival (PFS), Overall Survival (OS) and treatment-related toxicities 
are reported. 
Results: Between 2007 and 2012, 20 patients with a total of 24 lesions 
were treated with SBRT. Fourteen patients presented hepatocellular 
carcinoma (HCC), the others had either metastatic lesions from 
colorectal cancer (CRC) or cholangiocarcinoma. The median diameter 
of the lesions was 23 mm (5-98). The dose per fraction ranged from 6 
to 20 Gy with a median total dose of 60 Gy (range: 36-60 Gy). The 
dose was prescribed to the 80% isodose line covering the PTV. The 
median follow-up was 24 months. The actuarial LC rate was 78% for 
patients with HCC and 83% for those with adenocarcinoma and 
cholangiocarcinoma. Median OS was 37 months and OS rates were 88% 
at 12 and 24months. PFS was 65% and 53% at 6 and 24 months, 
respectively. Acute grade 3-4 toxicities occurred in 2 patients; a small 
proportion of the other patients experienced grade 1 or 2 toxicities. 
Conclusions: SBRT provides excellent local control with minimal side 
effects in selected patients.  
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Purpose/Objective: Describe Stereotactic Body RadioTherapy (SBRT) 
technique for treatment of this disease presentation 
Review Outcomes (Local Control, Overall Survival, and Toxicity) 
Materials and Methods: A total of 12 patients were treated with SBRT 
by the CyberKnife system between August 2009 and July 2012. All 
patients had initially presented with local/loco-regional disease. Six 
patients recurred with sternal metastases, six with Internal Mammary 
Chain (IMC) lymph node metastases. The Baseline Clinical 
Characteristics of the patients were well matched with respect to 
Age, Grade, Stage and Receptor Status at presentation. Median age at 
presentation was 45 years (Range= 30-63 years). Median Disease-Free 
Interval between presentation and relapse was 3 years (Range 1-38 
years). 2 patients that recurred in the Sternum had synchronous 
distant disease. 7 patients (58%) of the group as a whole were given 
Chemotherapy as the first treatment at the time of Sternal/IMC node 
recurrence. 10 patients (83%) had received prior conventional 
radiotherapy which overlapped with the target site.Median CTV-PTV 
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margin = 2.25mm (Range 1.25-3mm). Median PTV volume = 32cc 
(Range= 6-1879cc).Prescription dose was 30-36Gy in 3-5# (BED using 
α/β=10, 48-79). Dose was prescribed to the Median 64% isodose line 
(Range 48-78%). Median coverage was 98.3% (range 95.2-99.9%). 
Treatment delivery was tracked with fiducials and the Synchrony 
system. 
Results: Outcome data was available for 10 patients. Local Control 
rate was 100%. 4 patients (40%) progressed distantly, 2 in the IMC 
Node group, and 2 in the Sternum group. One of the patients that 
progressed distantly in the Sternal group had distant disease at the 
time of CyberKnife. Of those that progressed distantly, 75% had 
received chemotherapy as their first treatment at the time of 
Sternal/IMC node recurrence. Median Disease-Free Interval (DFI) in 
progressors was 2 years (Range 1-6 yrs), compared to a DFI in Non-
progressors of 3 years (Range 1-13 yrs). Median Progression-Free 
Survival for the IMC node group, Sternal group, and Cohort as a whole 
were 6, 2 and 4 months respectively. The follow-up data was, 
however, less mature for the Sternal group. Overall Survival (OS) rate 
was 90%. The patient that died was had Sternal recurrence patient 
with small lung metastases at the time of CyberKnife treatment. She 
died of lepto-meningeal disease. Median OS for IMC node group, 
Sternal group and Cohort as a whole were 16, 2 and 6 months 
respectively. However, follow-up data is less mature for the Sternal 
group. Treatment was well tolerated with only 25% of the group 
experiencing acute toxicity (G1). Only 1 patient experienced Late 
toxicity (fleeting G3 symptoms), the patient had received prior 
rdaiotherapy. 
Conclusions: SBRT is a feasible treatment approach for patients with 
Sternal/IMC nodal recurrence of Breast Cancer. The technique is well 
tolerated, even in those who have received prior Radiotherapy. The 
outcome data is still immature, but the early Local Control rates 
(100%), and Overall Survival rates (90%) at a Median follow-up of 11 
months are encouraging.  
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Purpose/Objective: The management of disease recurrence within a 
previously irradiated pelvic field is a challenging clinical problem. The 
ability to re-irradiate the pelvis to a therapeutically meaningful dose 
is limited by the cumulative dose received by adjacent pelvic organs 
at risk (OAR). The Cyberknife radiosurgery system enables highly 
conformal dosimetry with rapid dose fall off outside of the target. 
This, in combination with the use of small treatment margins 
facilitated by tumour tracking, make it a potentially attractive 
delivery platform for re-irradiation. 
The aim of this retrospective study was to review the toxicity and 
early efficacy data of patients receiving SBRT with the Cyberknife 
platform for pelvic re-irradiation at our institution. 
Materials and Methods: Patients receiving Cyberknife SBRT to 
abdominopelvic targets sited within a previously irradiated field were 
retrospectively identified. Details on primary site histology, prior 
external beam radiotherapy (EBRT), re-irradiation dose and indication 
for re-treatment were obtained from the patient’s electronic notes. 
Radiotherapy toxicity was graded using CTCAE v4.0. Follow up 
consisted of clinical examination and radiological assessment. In field 
local control and time to progression were calculated from the day of 
completing SBRT until the date of radiological evidence of progression 
using standard RECIST criteria. 
Results: 16 patients were treated between 01.08.11-01.11.12. Median 
follow up was 6 months (range 1-15). 8 patients had primary 
gynaecological malignancies, 7 colorectal and 1 melanoma. Median 
age was 59 years (range 27-85). Indications for re-irradiation were 
nodal recurrence (6), soft tissue recurrence (7) and positive margins 
following surgery (3). Median time from previous EBRT was 20 months 
(range 1-156). Median previous EBRT dose was 50.4 Gy (range 30-54) 
in 28 fractions (range 10-39). 3 patients with gynaecological primaries 
had also received prior brachytherapy. Median re-irradiation dose was 
30 Gy (range 18-35) in 3 fractions. 44% of patients had no recordable 
toxicity. 3 patients with pelvic side wall recurrences experienced G2 
pain during treatment, which resolved shortly after completion of 
SBRT. One patient developed a colovesical fistula 2 months after SBRT 
(G4 toxicity). This was associated with local disease recurrence 
therefore the aetiology was unclear. At last follow up, local control is 
94% (15/16 patients). A single patient had an in field recurrence 2 
months after SBRT. 6/16 patients (38%) have relapsed at distant sites. 
Median time to relapse at any site was 3 months (range 2-11). 
Conclusions: At this early time point of data analysis, minimal toxicity 
has been observed to date. Cyberknife SBRT is a promising method for 
pelvic re-irradiation and warrants further investigation.  
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Purpose/Objective: The use of autosegmentation computed systems 
in clinical setting for locally advanced rectal cancer is time sparing 
with an acceptable Dice Coefficient for CTV, Mean Dice Coefficient 
(MDC) of 0.70, while it does not reach an adequate value for small 
nodal subvolumes (MDC=0.67) (1). In this phase II study the objective is 
to verify in clinical setting the time sparing and the Dice Coefficient in 
bigger volumes (CTV and grouped nodal subvolumes) in locally 
advanced rectal cancer using the Smart Segmentation Knowledge 
Based Contouring (SS-KBC)® research program.  
(1) Clinical validation of atlas-based auto-segmentation of pelvic 
volumes and normal tissue in rectal tumors using autosegmentation 
computed system. Gambacorta et al, Acta Oncologica, in press 
Materials and Methods: 29 consecutive patients were selected 
between June and September 2012; images of 14 patients as atlas, 15 
for validation. To test the reliability of the system for bigger volumes, 
the nodal subvolumes were grouped according to clinical stage and 
site of the tumor (tab1). According to our ongoing QA program two 
operators were involved: a Delineator and a Reviewer. CTV and pelvic 
grouped nodal subsites were contoured by Delineator in 2 different 
sequences (A-manual vs B-autosegmentation) of contouring using the 
same planning CT; all of them underwent to Indipendent Check by 
Reviewer. To improve the reliability of the system many 
anthropometric characteristics where analyzed (including BMI, sex, 
age, fertility state, sacro-coccigeal distance and the most anterior 
distance between upper iliac crests). The analysis was conducted to 
test the reliability of the system using Dice Coefficient and the total 
time spared by the Delineator to complete the 2 different sequences. 
 
 
Results: In clinical practice the time spared by operator 1 to complete 
sequence A and B was of 14min vs 1min respectively; there was a 
statistically significant better MDC in favor of sequence A vs sequence 
B: 
-CTV: sequence A (MDC=0.86) vs sequence B (MDC=0.78), p=0.001 
(fig.1) 
-Subvolume 1: sequence A (MDC=0.86) vs sequence B (MDC=0.77), 
p=0.001 
-Subvolume 2a: sequence A (MDC=0.76) vs sequence B (MDC=0.66), 
p=0.001 
